

Supplemental Digital Content Table 1. Baseline characteristics in patients with multifocal FMD, by treatment option.

| | Conservative management | | Revascularization | | <i>p</i> |
|--|-------------------------|-------------|-------------------|-------------|----------|
| | No. | Value | No. | Value | |
| Male sex, <i>n</i> (%) | 195 | 32 (16) | 131 | 17 (13) | 0.43 |
| Age at diagnosis of hypertension, <i>years</i> | 193 | 44 [36, 52] | 130 | 36 [25, 43] | < 0.001 |
| Age at diagnosis of FMD, <i>years</i> | 195 | 54 [47, 63] | 131 | 41 [31, 50] | < 0.001 |
| Family history of hypertension, <i>n</i> (%) | 142 | 96 (68) | 86 | 53 (62) | 0.39 |
| Delay hypertension/FMD diagnosis, <i>years</i> | 193 | 7 [2, 17] | 130 | 3 [1, 9] | < 0.001 |
| Bilateral renal artery FMD, <i>n</i> (%) | 195 | 115 (59) | 130 | 78 (60) | 0,91 |
| History of dyslipidemia, <i>n</i> (%) | 178 | 60 (34) | 113 | 22 (19) | 0.01 |
| History of diabete, <i>n</i> (%) | 177 | 9 (5) | 112 | 3 (3) | 0.38 |
| Current smokers, <i>n</i> (%) | 175 | 29 (17) | 112 | 44 (39) | < 0.001 |
| Body mass index, <i>kg/m</i> ² | 176 | 24 [22, 27] | 99 | 22 [20, 25] | < 0.001 |

| | | | | | |
|---|-----|---------------|-----|----------------|---------|
| Systolic BP, <i>mmHg</i> | 176 | 145 [128,159] | 109 | 158 [142, 176] | < 0.001 |
| Diastolic BP, <i>mmHg</i> | 176 | 86 [75, 98] | 109 | 97 [86, 110] | < 0.001 |
| Treatment score, <i>n</i> | 176 | 2 [1, 3] | 108 | 2 [1, 3] | 0.65 |
| Controlled hypertension, <i>n (%)</i> | 176 | 66 (38) | 109 | 22 (20) | 0.002 |
| Creatinine clearance, <i>ml/min/1.73m²</i> | 165 | 85 [71, 98] | 94 | 85 [73, 100] | 0.68 |
| Creatinine clearance \leq 60 ml/min/1.73m ² , <i>n (%)</i> | 165 | 20 (12) | 94 | 5 (5) | 0.08 |

The number of patients (No.) available for analysis is shown for each variable. The values shown are the numbers of patients (percentage) for binary variables and the median [interquartile range] for quantitative variables.

BP, blood pressure; FMD, fibromuscular dysplasia

Supplemental Digital Content Table 2. Blood pressure and renal outcome at most recent visit in patients with multifocal FMD, by treatment option

| | Conservative management | | Revascularization | | <i>p</i> | <i>Adjusted p</i> |
|--|-------------------------|------------------|-------------------|------------------|----------|-------------------|
| | No. | Value | No. | Value | | |
| Median year of DFM diagnosis | 195 | 2006 [1999-2010] | 131 | 2000 [1993-2007] | < 0.001 | |
| Median follow up*, <i>months</i> | 158 | 28 [7, 64] | 99 | 50 [12, 127] | 0.006 | |
| <i>Age, years</i> | 173 | 60 [51, 67] | 116 | 48 [39, 60] | < 0.001 | |
| Decrease from baseline in systolic BP,** <i>mmHg</i> | 156 | -11 [-28, 5] | 95 | -27 [-44, -9] | < 0.001 | 0.18 |
| Decrease from baseline in diastolic BP,** <i>mmHg</i> | 156 | -6 [-20, 3] | 95 | -16 [-30, -6] | < 0.001 | 0.30 |
| Systolic BP at most recent visit, <i>mmHg</i> | 172 | 130 [118, 142] | 112 | 130 [118, 143] | 0.69 | 0.18 |
| Diastolic BP at most recent visit, <i>mmHg</i> | 172 | 78 [69, 83] | 112 | 78 [70, 86] | 0.23 | 0.30 |
| Treatment score at most recent visit, <i>n</i> | 171 | 2 [1, 3] | 113 | 1 [0, 3] | < 0.001 | 0.01 |
| BP at target, <i>n (%)</i> | 172 | 120 (70) | 112 | 73 (65) | 0.44 | 0.15 |
| Hypertension cure in revascularized patients, <i>n (%)</i> | - | - | 112 | 21 (19) | - | - |

| | | | | | | |
|---|-----|--------------|-----|--------------|---------|------|
| Estimated creatinine clearance, <i>ml/min/1.73m²</i> | 122 | 80 [63, 100] | 92 | 82 [72, 102] | 0.17 | 0.10 |
| Creatinine clearance \leq 60 ml/min/1.73m ² , <i>n (%)</i> | 122 | 22 (18) | 92 | 10 (11) | 0.33 | 0.60 |
| Creatinine clearance \leq 30 ml/min/1.73m ² , <i>n (%)</i> | 122 | 1 (1) | 92 | 0 (0) | 1 | 0.65 |
| Patients with renal complications, <i>n (%)</i> | 193 | 41 (21) | 130 | 51 (39) | < 0.001 | 0.07 |

The number of patients (No.) available for analysis is shown for each variable. The values shown are the numbers of patients (percentage) for binary variables and the median [interquartile range] for quantitative variables.

* p value adjusted for ages at FMD diagnosis and follow-up visit; sex; bilateral RAS; baseline BP level, treatment score and BMI by analysis of covariance.

**Among patients who attended both baseline and follow-up visits at this unit.

BP, blood pressure; FMD, fibromuscular dysplasia